RxDoctor Payments Data

Denise Lano, PA

Physician Assistant · Wilmington, DENPI 1861581969

Payments from drug & device makers

$1,053in general payments, 2019–2025

Across 48 payments — averaging $21.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$300
  • Lilly USA, LLC$163
  • Boehringer Ingelheim$113
  • Novo Nordisk$84
  • Pfizer$81
  • Exact Sciences$80
  • plus $232 from 6 others

What the payments were for

  • Food & beverage$1,053100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,053 in reported general payments places this provider in the 75th percentile of 527 physician assistant providers in Delaware.

See all physician assistant providers in Delaware

Medicare billing

Part B allowed, 2024
$50,173
Medicare patients
191
Services billed
632

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide11$16,704
MounjaroTirzepatide11$11,444
Rosuvastatin Calcium72$1,252
Atorvastatin Calcium55$697
Albuterol Sulfate HfaAlbuterol Sulfate18$627
Metoprolol Succinate32$529
Amlodipine Besylate47$513
Losartan Potassium32$399
Metformin Hcl33$363
Gabapentin16$338
Levothyroxine Sodium30$334
Fluticasone Propionate15$298
Lisinopril34$254
Omeprazole17$247
Simvastatin21$231

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$84$16,70411 claims
Lilly USA, LLCMounjaro$163$11,44411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 527 physician assistant providers in Delaware.

Other physician assistant in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →